Archer Materials Ltd
ASX:AXE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Archer Materials Ltd
ASX:AXE
|
AU |
|
F
|
Fodelia Oyj
OMXH:FODELIA
|
FI |
|
ZTO Express (Cayman) Inc
HKEX:2057
|
CN |
|
Realtek Semiconductor Corp
TWSE:2379
|
TW |
|
Beijing Haixin Energy Technology Co Ltd
SZSE:300072
|
CN |
|
T
|
Talam Transform Bhd
KLSE:TALAMT
|
MY |
|
Touchwood Entertainment Ltd
NSE:TOUCHWOOD
|
IN |
|
Urbi Desarrollos Urbanos SAB de CV
BMV:URBI
|
MX |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Armac Locacao Logistica e Servicos SA
BOVESPA:ARML3
|
BR |
|
C
|
Cressanda Solutions Ltd
BSE:512379
|
IN |
|
A
|
A & W Food Services of Canada Inc
TSX:AW
|
CA |
Archer Materials Ltd
Archer Materials Ltd. focuses on developing and commercializing global industries of quantum technology, human health, and reliable energy. The company is headquartered in Adelaide, South Australia. The company went IPO on 2007-08-14. The firm is focused on developing and commercializing deep technology, including quantum computing and biotech. The firm is progressing the development of 12CQ quantum computing processor chip and A1 Biochip lab-on-a-chip technology. The 12CQ chip allow for quantum computing onboard mobile devices for speed ups and increased power in artificial intelligence, big data, and fintech applications. The firm is developing biochip using graphene-based materials as integrated circuits, to form the sensing elements in its biochip.
Archer Materials Ltd. focuses on developing and commercializing global industries of quantum technology, human health, and reliable energy. The company is headquartered in Adelaide, South Australia. The company went IPO on 2007-08-14. The firm is focused on developing and commercializing deep technology, including quantum computing and biotech. The firm is progressing the development of 12CQ quantum computing processor chip and A1 Biochip lab-on-a-chip technology. The 12CQ chip allow for quantum computing onboard mobile devices for speed ups and increased power in artificial intelligence, big data, and fintech applications. The firm is developing biochip using graphene-based materials as integrated circuits, to form the sensing elements in its biochip.
Funding & runway: Cash of $10 million with a current burn of about $2 million a quarter; management does not expect burn to change significantly for the rest of the year.
Technology progress: Management says the business has moved from early research into development — alpha biochip prototypes exist and technical derisking on qubits and sensors has advanced.
Patents ramp: 40 patents filed globally and management expects to significantly ramp filings and to double this over the coming year.
Commercialisation focus: Biochip has unlocked early commercial discussions (pharma, medtech); biochip beta prototype targeted mid-year and clinical trials targeted for 2027.
Quantum milestones: Qubit readout progress and an initial qubit demo targeted mid-year; quantum machine learning (QML) project with CSIRO is 1 year from January with early indicators mid-year and a demo by end of 2026.
New applications pipeline: QML first use-case is fraud detection (financial); other target areas discussed include healthcare imaging, logistics, sensing (TMR) for defence/aerospace, lithium sensing in blood and agtech/industrial biochip use-cases.
Commercial partnerships: Early-stage commercial discussions have begun, especially for the biochip; broader partner/licensing discussions expected to accelerate after mid-year demos and data.
